**Question:** Mechanism of action of teduglutide in short bowel syndrome:-

A. Increases intestinal mass
B. Increases intestinal blood flow
C. Promotes intestinal secretion
D. Directly stimulates intestinal motility

**Core Concept:**
Short bowel syndrome (SBS) is a condition characterized by a significant reduction in the small intestine's functional length, leading to malabsorption and malnutrition. Teduglutide is a synthetic analog of the gut hormone glucagon-like peptide-2 (GLP-2), which plays a crucial role in maintaining small bowel integrity and promoting intestinal adaptation in conditions like SBS.

**Why the Correct Answer is Right:**
Teduglutide acts as a GLP-2 receptor agonist, binding to the GLP-2 receptor on the surface of intestinal cells. This binding activates several intracellular signaling pathways, leading to the following key mechanisms:

1. Increases intestinal mass: By activating the GLP-2 receptor, teduglutide stimulates the proliferation of intestinal cells, including crypt cells and goblet cells, which enhances the growth of the remaining small bowel.
2. Promotes intestinal secretion: Teduglutide increases the secretion of chloride ions and water into the intestinal lumen, leading to increased intestinal secretion and, ultimately, improved nutrient absorption.
3. Directly stimulates intestinal motility: Although teduglutide primarily focuses on the above mechanisms, it also indirectly stimulates intestinal motility by promoting the growth and function of the remaining small bowel.

**Why Each Wrong Option is Incorrect:**
A. Teduglutide does not primarily increase intestinal mass by directly stimulating the production of intestinal cells. Instead, it promotes the growth and function of the remaining small bowel, which indirectly contributes to increased intestinal mass.
B. Teduglutide does not primarily focus on increasing intestinal blood flow but rather promotes intestinal adaptation and improves nutrient absorption.
C. Teduglutide primarily promotes intestinal adaptation and nutrient absorption, with secretion and motility as secondary effects rather than promoting direct secretion or motility.

**Clinical Pearl:**
Teduglutide is a valuable therapeutic option for patients with SBS, as it enhances intestinal adaptation, promotes nutrient absorption, and improves overall gut function. By focusing on intestinal adaptation and function, teduglutide helps to mitigate the complications associated with SBS, such as malnutrition and electrolyte imbalances.